In the KEGG pathway enrichment, MAPK signaling pathway, PI3K-AKT signaling pathway, proteoglycan in cancer, Ras signaling pathway, hepatitis B, and other pathways mostly occupied the forefront, indicating that OMT may treat itching by suppressing inflammation-related signaling pathways. This evidence concerns the gene AKT1 and hepatitis B virus infection.